A 12-Step Desensitization Protocol for Calaspargase Pegol-mknl

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Asparaginase is a cornerstone therapy for childhood acute lymphoblastic leukemia (ALL).
• Hypersensitivity reactions (HSRs) to bacterial asparaginase limit its use, even with PEGylated formulations like pegaspargase.
• Recombinant asparaginase Erwinia chrysanthemi is an alternative, but HSRs can still occur.

Purpose of the Study:

• To report a case of a pediatric patient with relapsed ALL experiencing HSRs to both pegaspargase and recombinant Erwinia asparaginase.
• To describe a novel desensitization protocol for calaspargase pegol-mknl in a patient with multiple prior HSRs.
• To evaluate the safety and efficacy of this desensitization protocol, assessing for adverse events and serum asparaginase activity.

Main Methods:

• Case report of an 11-year-old boy with relapsed ALL.
• Administration of a novel desensitization protocol for calaspargase pegol-mknl.
• Monitoring for hypersensitivity reactions and assessment of serum asparaginase activity.

Main Results:

• The patient experienced HSRs to both pegaspargase and recombinant Erwinia asparaginase.
• The novel desensitization protocol for calaspargase pegol-mknl was administered without any adverse events.
• Adequate serum asparaginase activity was maintained throughout the treatment.

Conclusions:

• This case demonstrates the successful use of a novel desensitization protocol for calaspargase pegol-mknl in a pediatric patient with acute lymphoblastic leukemia who had prior hypersensitivity reactions.
• The protocol was safe and effective, allowing for continued treatment with adequate therapeutic drug levels.